Like I said, stick around and see for yourself. Patience is a virtue. Upcoming catalysts include: Uplisting to OTCQB after new ticker. Major IR/PR push after ticket change/uplist. Submission of Prolanta™ for Orphan Designation in the European Union. The company has identified 2 other drugs that they are looking to acquire. Adding more prestigious board members and a world-class scientific advisory board. Clinical results relating to Prolanta™. MD Anderson will soon evaluate Prolanta™ for the treatment of endometrial cancer. The company is currently pursuing a licensing partner for Prolanta™ in Asia. Planning for Nasdaq uplist next year.